SCHEMBL1840169

SCHEMBL1840169

O=c1[nH]c(-c2ccc3[nH]c(-c4ccc(F)cc4)nc3c2)no1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.58
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PARP1 P09874 1/20 0.46
GUSB P08236 1/20 0.46
NR4A2 P43354 1/20 0.46
ALDH1A1 P00352 2/20 0.45
PKM P14618 1/20 0.45
CHEK2 O96017 3/20 0.44
TNKS O95271 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
TCF4 P15884 1/20 0.41
CTNNB1 P35222 1/20 0.41
DHODH Q02127 1/20 0.41
RARB P10826 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22273714 0.83 ALOX5 (0.63) ALOX5PARP1ALDH1A1TNKSTNKS2
SCHEMBL4373640 0.78 KDM4E (0.69) KDM4ENPC1RAB9ASMN1; SMN2GUSB
SCHEMBL5377210 0.75 ALOX5 (0.57) ALOX5ALDH1A1DHODH
SCHEMBL17393283 0.74 PSMD11 (0.53) ALOX5KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL7250551 0.73 ALOX5 (1.00) ALOX5KDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL26753826 0.73 KDM4E (0.61) KDM4ENPC1RAB9ASMN1; SMN2GUSB
SCHEMBL3333026 0.73 KDM4E (0.61) KDM4ENPC1RAB9ASMN1; SMN2GUSB
SCHEMBL8472844 0.73 MEN1 (0.63) ALOX5KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL30518050 0.72 ALDH1A1 (0.47) ALOX5PARP1ALDH1A1RARB
SCHEMBL18603139 0.72 ALDH1A1 (0.49) ALOX5ALDH1A1RARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168665-B2 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-01 US claimed
EP-2079709-B1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-05-18 EP claimed
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2009-09-24 US claimed
EP-2079709-A1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-07-22 EP claimed
WO-2008037381-A1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-04-03 WO claimed
EP-1905764-A1 Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals Sanofi-Aventis (FR) 2008-04-02 EP claimed
US-8168665-B2 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-01 US disclosed
US-8168665-B2 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-01 US disclosed
US-8168665-B2 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-01 US disclosed
EP-2079709-B1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-05-18 EP disclosed
EP-2079709-B1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-05-18 EP disclosed
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2009-09-24 US disclosed
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2009-09-24 US disclosed
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2009-09-24 US disclosed
EP-2079709-A1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-07-22 EP disclosed
WO-2008037381-A1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-04-03 WO disclosed
WO-2008037381-A1 SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-04-03 WO disclosed
EP-1905764-A1 Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals Sanofi-Aventis (FR) 2008-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239915-A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals NOS2, NOS3, NOS1 ALOX5 1570/4885KDM4E 489/4885NPC1 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.